Mobile website
Archive > Volume 26 Issue 5 > 2019,26(5):485-491. DOI:10.3872/j.issn.1007-385X.2019.05.001 Prev Next
Expert Forum
Hyperprogressive disease in cancer patients with immune checkpoint inhibitor therapy and its coping strategies
- Article
- Figures
- Metrics
- Preview PDF
- Reference
- Related
- Cited by
- Materials
Abstract:
[Abstract] Successful targeting and inhibition of the programmed cell death-1/ programmed cell death-ligand 1 immune checkpoint pathways by monoclonal antibody stimulates an immune response against tumors, has led to a rapidly expanding repertoire of immune checkpoint inhibitors (ICIs) for the treatment of various cancers. Immune checkpoint therapy has dramatically changed the therapeutic landscape of certain types of cancers. However, hyperprogressive disease (HPD) is emerging as a new pattern of progression in cancer patients treated with ICIs, characterized as an absolute increase in the tumor growth rate exceeding 50% per month. This article discusses the concept of HPD, hypotheses as to the underlying biology, and what needs to be done to better understand and identify strategies to prevent or overcome HPD related to checkpoint blockade therapy.
Keywords:
Project Supported:
Project supported by the National Natural Science Foundation of China (No. 81672354), the Shanghai Science and Technology Commission International Cooperation Project (No. 18410720200), and the Shanghai Municipal Education Commission-Gaofeng Clinical Medicine Grant Support (No. 20172017)
Clc Number:
